

NHS BSW ICB commissions the use of prescribable CGM sensors for patients 2 years and older with Type 1 diabetes, Type 2 diabetes & Type 3c diabetes in restricted circumstances, in line with national criteria below.

Formulary status of rtCGM (real time Continuous Glucose Monitoring) sensors

GREEN – initiation by or after advice and guidance from diabetes specialist healthcare professional

- **Dexcom One®+ - aged 2 years and over**
- **Freestyle Libre 2 Plus® sensors - aged 2 years and over**
- **Accucheck Smartguide® sensors- adults aged 18 years and over**

For group 6 below only: Hybrid closed loop only:

RED - prescribed and supplied by acute trusts only.

- **Freestyle Libre 3 Plus® sensors – aged 2 years and over, and only for use with the mylife Loop AID system within Hybrid Closed Loop Plan**

Approved indications

1. People with Type 1 diabetes

2. People with Type 2 diabetes who receive multiple daily injections (defined as “two or more daily insulin injections, which could either be a basal-bolus regimen or more than one daily insulin injection” by NICE NG28) of insulin in the following circumstances after diabetes specialist approval:

a. People prescribed multiple daily doses of insulin with severe, recurrent hypoglycaemia occurring weekly or monthly, or hypoglycaemia unawareness despite a high level of care to include:

- Regular finger prick testing,
- Education by specialist diabetes teams,
- Education to support insulin adjustment,

AND

- A medical review to exclude alternative causes

b. People prescribed multiple daily doses of insulin where patients are adjusting insulin doses **AND** the patient or carer cannot safely use finger prick testing, or where prescribable CGM enables significant independence to self-care in those with a physical disability (e.g. visual impairment) or learning disability.

c. People prescribed multiple daily doses of insulin and have been advised by a specialist diabetes healthcare professional to monitor their blood sugars ≥ 8 times/day using finger prick testing and can evidence with subsequent sustained improvement time in range. Where no benefit is evidenced after 6 months then the recommending specialist healthcare professional should stop the device.

d. Where a therapeutic trial 2-week trial is required to understand any new control issues that may have arisen and what may be causing them (i.e. through 2-week trial offer and equipment). Continuation is only supported where the commissioning criteria are met in a, b, c.

3. Pregnant women with type 2 diabetes

Reference:	Policy Name	Date of BSW APC	Review Date	Version
BSWICB-CP052	CGM sensor policy	Apr 2026	November 2027	007

4. Children and young people with type 2 diabetes who are on insulin therapy

5. People with other forms of diabetes:

- A) type 3c diabetes who are on insulin therapy e.g. cystic fibrosis associated diabetes
B) People living with any form of diabetes who are on haemodialysis and insulin treatment

Other requirements include:

- Use of shared decision-making tool to support device choice
- If multiple devices meet the needs and preferences, the device with the lowest cost should be offered
- Education on Continuous Glucose Monitoring has been provided (online or in person)
- Agree to use CGM sensor more than 70% of the time and collect at least 70% of data.
- Agree to regular reviews with the local clinical team.

6. People using the mylife Loop AID system

- A) Freestyle Libre 3 Plus sensors may be prescribed for patients using the mylife Loop AID system only within the hybrid closed loop plan.

RELEVANT NICE GUIDANCE

NICE guideline NG17. Type 1 diabetes in adults: diagnosis and management - [Overview | Type 1 diabetes in adults: diagnosis and management | Guidance | NICE](#)

NICE guideline NG28. Type 2 diabetes in adults: management [Overview | Type 2 diabetes in adults: management | Guidance | NICE](#)

NICE Guideline NG3. Diabetes in pregnancy: management from preconception to the postnatal period. [Overview | Diabetes in pregnancy: management from preconception to the postnatal period | Guidance | NICE.](#)

NICE technology appraisal TA943 - [Overview | Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes | Guidance | NICE](#)

PBR STATUS	In tariff
PATIENT BENEFITS	On-going use should demonstrably improve an individual's diabetes self-management e.g. improvement of HbA1c or Time In Range; improvement in symptoms such as diabetic ketoacidosis or hypoglycaemia; or improvement in psycho-social wellbeing.
COSTS	<ul style="list-style-type: none"> • Freestyle Libre 2 Plus® - aged 2 years and over £912.50 per year • Dexcom One+® - aged 2 years and over £900 per year • Freestyle Libre 3 Plus® - aged 4 years and over £1,095 per year • Accucheck Smartguide®- adults £912.50
SENSOR LIFESPAN	Dexcom One®+ – 10 days Freestyle Libre 2 Plus – 15 days Accucheck Smartguide® 14 days

Version control:

Version	Author	Purpose/change	Date
Apr 2026 (007)	Rachel Hobson	<ul style="list-style-type: none"> • Amended the traffic light status of rtCGM sensors to green as per APC decision Apr 26 • Removed need for a 6 month review 	6/5/26

Reference:	Policy Name	Date of BSW APC	Review Date	Version
BSWICB-CP052	CGM sensor policy	Apr 2026	November 2027	007